Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$2.44 USD
-0.01 (-0.41%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $2.43 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.44 USD
-0.01 (-0.41%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $2.43 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Bruker (BRKR) Q2 Earnings Meet Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Mettler-Toledo (MTD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Mettler-Toledo (MTD) delivered earnings and revenue surprises of 7.22% and 2.48%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Q1 Earnings Match Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0% and 4.92%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Q1 Earnings Beat Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 15.22% and 0.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?
by Zacks Equity Research
Here is a sneak peek into how five technology stocks, MANH, MSCI, AEYE, HBIO and TXN, are expected to fare in their quarterly results slated to be released on Apr 23.
Harvard Bioscience (HBIO) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -20% and 2.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 4.17% and 5.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Momentum in Harvard Bioscience (HBIO) Should Keep going
by Zacks Equity Research
Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
3 Instruments Stocks to Watch From a Prospering Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Harvard Bioscience (HBIO), Mettler-Toledo (MTD) and Waters (WAT) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.
Here's What Could Help Harvard Bioscience (HBIO) Maintain Its Recent Price Strength
by Zacks Equity Research
Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
5 High-Flying Tech Stocks With Solid Growth Potential
by Sweta Killa
Investors should consider stocks like Harvard Bioscience (HBIO), MicroStrategy (MSTR), Meta Platforms (META), InterDigital (IDCC), and Weave Communications (WEAV) in their portfolio if they want to outperform the broader market.
What Makes Harvard Bioscience (HBIO) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Harvard Bioscience (HBIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -120% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Meets Q2 Earnings Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Harvard Bioscience (HBIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Harvard Bioscience (HBIO) stock based on the movements in the options market lately.
Harvard Bioscience (HBIO) Loses 35.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Harvard Bioscience (HBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Harvard Bioscience (HBIO) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -20% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 15.87% and 6.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Q3 Earnings Meet Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 20.00% and 6.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You Looking for a Top Momentum Pick? Why Harvard Bioscience (HBIO) is a Great Choice
by Zacks Equity Research
Does Harvard Bioscience (HBIO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Harvard Bioscience (HBIO) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
Harvard Bioscience (HBIO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
4 Breakout Stocks You Must Add Right Away to Your Portfolio
by Nitish Marwah
The logic behind this strategy for stock selection is to identify stocks that are trading within a narrow band.